Novo Nordisk A/S (NVO) caught a major win Tuesday as the FDA greenlit its Wegovy pill, sending shares soaring nearly 10%.

The Approval That Matters

This isn't just another drug approval. Novo Nordisk's GLP-1 pill marks the first approval of its kind globally, which is a pretty big deal in the weight loss medication space. Until now, patients dealing with GLP-1 treatments have largely relied on injections, so a pill version opens up new possibilities.

The company plans to launch the medication with a starting dose of 1.5 milligrams. Expect to see it hit pharmacies and select telehealth providers in early January, with a price tag of $149 per month.

The TrumpRx Connection

Here's an interesting wrinkle: Patients paying out of pocket can also purchase the pill through President Donald Trump's direct-to-consumer platform, TrumpRx, at that same $149 monthly rate. That agreement was reached last month, giving patients another option beyond traditional pharmacy channels.

Market Reaction

Investors clearly liked what they heard. At the time of the announcement, Novo Nordisk shares were trading 9.71% higher at $52.55, up from around $48.10 earlier in the session. That's the kind of pop you get when the FDA hands you the first-ever approval in a major drug category.

For context, this approval puts Novo Nordisk in an interesting position against competitors in the weight loss medication market, where the race to develop more convenient treatment options continues to heat up.